Covalon Technologies

Covalon Technologies OCF Margin

The Operating Cash Flow Margin of Covalon Technologies (COV.V) as of Oct 15, 2026 is 6.98 %. In the previous year, Operating Cash Flow Margin was 11.14 % — a change of -37.40% (lower).

OCF Margin

6.98 %

YoY

-37.40%

Last updated:

Operating Cash Flow Margin of Covalon Technologies is 2025 6.98 % . Operating Cash Flow Margin of Covalon Technologies was 2024 11.14 % . It decreases by -37.40% lower compared to the previous year.

The Covalon Technologies OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-2.45 CAD
Jan 1, 2019
-8.31 CAD
Jan 1, 2020
-15.60 CAD
Jan 1, 2021
3.18 CAD
Jan 1, 2022
-44.05 CAD
Jan 1, 2023
-11.97 CAD
Jan 1, 2024
11.14 CAD
Jan 1, 2025
6.98 CAD
The Covalon Technologies OCF Margin history
YEAROCF MarginYoY
6.98 %-37.40%
11.14 %-193.07%
-11.97 %-72.82%
-44.05 %-1,486.76%
3.18 %-120.36%
-15.60 %+87.78%
-8.31 %+238.76%
-2.45 %-4,522.35%
0.06 %-100.36%
-15.29 %-48.86%
-29.89 %-187.29%
34.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Covalon Technologies Stock analysis

What does Covalon Technologies do? Covalon Technologies Ltd, listed on the TSX Venture Exchange under the ticker COV.V, is a biotechnology company based in Mississauga, Ontario, Canada. Founded in 2004, the company went public on September 3, 2004, with its initial public offering. Covalon specializes in the research, development, manufacturing, and marketing of patent-protected medical products. The company focuses on advanced wound care, infection prevention, and medical device coatings, offering solutions designed to reduce infections, minimize pain, and improve patient outcomes. Its products include specialized medical devices, medical dressings, and advanced technologies for perioperative care, antimicrobial skin protection, and complex wound closure. Covalon operates through two primary business models: developing and selling its own branded products and collaborating with other medical companies through development and licensing agreements. The company emphasizes compassionate care, creating products that are both patient-friendly and tailored for healthcare providers. Headquartered in Mississauga, Covalon leverages its patented technology platforms to address critical needs in medical care, particularly in reducing post-surgical infections and enhancing recovery processes. The company's solutions are intended to support both patients and medical professionals by providing effective, innovative approaches to wound management and infection control. Covalon's portfolio reflects a commitment to advancing medical technology with a focus on practical, patient-centered applications. Covalon Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Covalon Technologies stock

Operating Cash Flow Margin of Covalon Technologies is 6.98 % in 2025.

Operating Cash Flow Margin of Covalon Technologies changed from 11.14 % to 6.98 %, representing a -37.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Covalon Technologies since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Covalon Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Covalon Technologies

All Key Metrics — Covalon Technologies